FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 357:1365-1368 October 4, 2007 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In a trend that has received surprisingly little attention, contract research organizations (CROs) have gradually taken over much of academia's traditional role in drug development over the past decade. They've been able to do so by offering greater speed and efficiency in conducting clinical trials than academic groups can, but questions have been raised about their qualifications, ethics, accountability, and degree of independence from their pharmaceutical-industry clients.

Annual CRO-industry revenues have increased from about $7 billion in 2001 to an estimated $17.8 billion today; of more than 1000 CROs in operation, the four largest — Quintiles, Covance, Pharmaceutical Product Development . . . [Full Text of this Article]

Source Information

Dr. Shuchman is a national correspondent for the Journal.

This article has been cited by other articles:

• Liesegang, T. J. (2008). Commercialism, Loss of Professionalism, and the Effect on Journals. Arch Ophthalmol 126: 1292-1295 [Full Text]  
• Lenzer, J. (2008). Truly independent research?. BMJ 337: a1332-a1332 [Full Text]  
• Psaty, B. M., Kronmal, R. A. (2008). Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation. JAMA 299: 1813-1817 [Abstract] [Full Text]